Biotech · Public company · Vero Beach, FL, US
Processa Pharmaceuticals, Inc.
Ticker PCSA · SEC CIK 0001533743
Track this companyFree. Adds Processa Pharmaceuticals, Inc. to your Dealase workspace and tells you when its record changes.
Clinical trials90 recruiting or active
Pipeline programs8From trials and the company's site
Disclosed deals0None found yet
Cash runwayNot availableNo recent cash burn filed
Pipeline8
- CapecitabinePhase 2 · Breast CancerClinicalTrials.gov · fetched Nov 12, 2026
- HT-100Phase 2 · Duchenne Muscular DystrophyClinicalTrials.gov · fetched Nov 12, 2026
- PCS12852Phase 2 · GastroparesisClinicalTrials.gov · fetched Nov 12, 2026
- PCS499Phase 2 · Necrobiosis LipoidicaClinicalTrials.gov · fetched Nov 12, 2026
- PCS6422 and capecitabinePhase 2 · Breast CancerClinicalTrials.gov · fetched Nov 12, 2026
- RX-3117Phase 2 · Solid TumorClinicalTrials.gov · fetched Nov 12, 2026
- RX-3117Phase 2 · Metastatic Pancreatic CancerClinicalTrials.gov · fetched Nov 12, 2026
- PCS6422 and capecitabinePhase 1 · Advanced CancerClinicalTrials.gov · fetched Nov 12, 2026
Clinical trials9
- A Phase 2 Study of PCS6422 With Capecitabine in Patients With Advanced or Metastatic Breast CancerPHASE2 · TERMINATED · started Oct 2, 2024ClinicalTrials.gov NCT06568692 · fetched Nov 12, 2026
- Safety, PK and Efficacy of PCS12852 on Gastric Emptying Rate in Patients With Moderate to Severe GastroparesisPHASE2 · COMPLETED · started Mar 9, 2022ClinicalTrials.gov NCT05270460 · fetched Nov 12, 2026
- A Study of the Safety and PK of PCS6422 (Eniluracil) with Capecitabine in Patients with Advanced, Refractory GI Tract TumorsPHASE1 · COMPLETED · started Jun 18, 2021ClinicalTrials.gov NCT04861987 · fetched Nov 12, 2026
- A Clinical Trial to Evaluate PCS499 in Treating Ulcerations in Patients Who Have Necrobiosis LipoidicaPHASE2 · TERMINATED · started Apr 12, 2021ClinicalTrials.gov NCT04800562 · fetched Nov 12, 2026
- A Study to Evaluate the Safety and Tolerability of PCS499 for the Treatment of Necrobiosis LipoidicaPHASE2 · COMPLETED · started Nov 7, 2018ClinicalTrials.gov NCT03698864 · fetched Nov 12, 2026
- RX-3117 in Combination With Abraxane® in Subjects With Metastatic Pancreatic CancerPHASE1_PHASE2 · COMPLETED · started Oct 2, 2017ClinicalTrials.gov NCT03189914 · fetched Nov 12, 2026
- Dose-Finding and Safety Study for Oral Single-Agent to Treat Advanced MalignanciesPHASE1_PHASE2 · COMPLETED · started Dec 1, 2013ClinicalTrials.gov NCT02030067 · fetched Nov 12, 2026
- Open Label Extension Study of HT-100 in Patients With DMDPHASE2 · TERMINATED · started Oct 1, 2013ClinicalTrials.gov NCT01978366 · fetched Nov 12, 2026
- Safety, Tolerability, and Pharmacokinetics of Single and Multiple Doses of HT-100 in Duchenne Muscular DystrophyPHASE1_PHASE2 · TERMINATED · started May 1, 2013ClinicalTrials.gov NCT01847573 · fetched Nov 12, 2026
SEC filings12
- 8-K · 8-KSEC EDGAR · filed Nov 5, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Nov 4, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Oct 29, 2026 · fetched Nov 12, 2026
- 8-K/A · 8-K/ASEC EDGAR · filed Oct 5, 2026 · fetched Nov 12, 2026
- 10-Q · 10-QSEC EDGAR · filed Aug 14, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Aug 4, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Jul 29, 2026 · fetched Nov 12, 2026
- 10-Q · 10-QSEC EDGAR · filed May 7, 2026 · fetched Nov 12, 2026
- 10-K/A · 10-K/ASEC EDGAR · filed Apr 30, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Apr 30, 2026 · fetched Nov 12, 2026
- 10-K · 10-KSEC EDGAR · filed Mar 18, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Feb 19, 2026 · fetched Nov 12, 2026